Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2024 | 2024-10-31 | $210,000 | reported | |
| FY 2023 | 2023-10-31 | $210,000 | reported | |
| FY 2021 | 2021-10-31 | $512,000 | reported | |
| FY 2019 | 2019-10-31 | $250,000 | reported | |
| FY 2018 | 2018-10-31 | $1,112,500 | reported | |
| FY 2017 | 2017-10-31 | $362,500 | reported | |
| FY 2016 | 2016-10-31 | $300,000 | reported | |
| FY 2015 | 2015-10-31 | $9,255,000 | reported | |
| FY 2014 | 2014-10-31 | $3,667,320 | reported | |
| FY 2013 | 2013-10-31 | $388,850 | reported | |
| FY 2012 | 2012-10-31 | $940,010 revised | reported | |
| FY 2011 | 2011-10-31 | $1,003,193 | reported |
Anixa Biosciences Inc · CIK 715446 · Engraved from SEC EDGAR
FY2025 figures · derived
Anixa Biosciences Inc is the 310th largest of the 566 covered companies the SEC files under this code, by market cap. SIC 2834
Latest filing Sep 30, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | — | $6.00K | $6.00K | — | 32.20M sh | +1.6% | — |
63 managers · Quarter ended Jun 30, 2026All holders ›
10